Lung cancer in never smokers--a review.

By S. Couraud, G. Zalcman, B. Milleron, F. Morin, P. Souquet. European Journal of Cancer, 2012

902 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Recent Insights into Particulate Matter (PM2.5)-Mediated Toxicity in Humans: An Overview (2022, background): “Furthermore, CXCL13 serum concentrations increased in mice prior to the appearance of a lung tumor detectable by microCT [163,164].”
Non-small cell lung cancer: current treatment and future advances. (2016, background): “Adenocarcinoma is the most common type of lung cancer in smokers and nonsmokers in men and women regardless of their age (7).”
EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII). (2015, background): “Adenocarcinoma (ADC) is one of the most common histological subtypes of NSCLC [3, 4].”
First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. (2012, background): “These activating mutations are present more frequently in patients with adenocarcinoma, never-smokers, women, and patients of Asian ethnicity.(4-6) Compared with patients with a history of smoking, approximately four-fold higher response rates with gefitinib in never-smokers with lung adenocarcinoma”